Immunovant Inc (IMVT)

Overview News Price History Option Chain Why IMVT Down? Discussions Forecast

Immunovant Inc stock is currently priced at $28.43, with a 24-hour trading volume of 1.79M. It has seen a -6.48% decreased in the last 24 hours and a -6.88% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $30.36 pivot point. If it approaches the $28.52 support level, significant changes may occur.

Immunovant Inc Stock (IMVT) Financials Data

Immunovant Inc (IMVT) Net Income 2024

IMVT net income (TTM) was -$243.45 million for the quarter ending December 31, 2023, a -22.52% decrease year-over-year.

Immunovant Inc (IMVT) Cash Flow 2024

IMVT recorded a free cash flow (TTM) of -$210.56 million for the quarter ending December 31, 2023, a -27.11% decrease year-over-year.

Immunovant Inc (IMVT) Earnings per Share 2024

IMVT earnings per share (TTM) was -$1.84 for the quarter ending December 31, 2023, a -10.84% decline year-over-year.

Immunovant Inc Stock (IMVT) Latest News

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks

Zacks Investment Research

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Zacks Investment Research

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Initiated	Wolfe Research: Outperform	Feb-15-24
Initiated	Deutsche Bank: Buy	Dec-12-23
Upgrade	UBS: Neutral → Buy	Oct-13-23
Upgrade	Raymond James: Mkt Perform → Outperform	Sep-26-23
Initiated	BofA Securities: Buy	May-01-23
Initiated	Citigroup: Buy	Apr-25-23
Initiated	Piper Sandler: Overweight	Mar-31-23
Initiated	Stifel: Buy	Mar-30-23
Initiated	Cantor Fitzgerald: Overweight	Feb-15-23
Upgrade	Guggenheim: Neutral → Buy	Feb-13-23
Upgrade	Wells Fargo: Equal Weight → Overweight	Jan-03-23
Downgrade	UBS: Buy → Neutral	Sep-26-22
Initiated	Wells Fargo: Equal Weight	Dec-08-21
Downgrade	Robert W. Baird: Outperform → Neutral	Aug-03-21
Downgrade	Credit Suisse: Neutral → Underperform	Aug-02-21
Downgrade	Guggenheim: Buy → Neutral	Jun-01-21
Downgrade	Stifel: Buy → Hold	Jun-01-21
Initiated	UBS: Buy	Oct-28-20
Initiated	Guggenheim: Buy	Oct-12-20
Initiated	Stifel: Buy	Oct-08-20
Initiated	Credit Suisse: Outperform	Oct-02-20
Reiterated	H.C. Wainwright: Buy	Aug-26-20
Initiated	Raymond James: Outperform	Aug-25-20
Initiated	H.C. Wainwright: Buy	Jul-29-20
Initiated	SVB Leerink: Outperform	Feb-24-20